About this trial
The post-hepatotectomy liver failure (PHLF) is still the most worrisome complication of hepatic resection. Surgeons have always been making efforts to preoperatively predict PHLF using kinds of techniques, scoring systems, and variables. The investigators of this study tried to create an individual predictive model based on the variable, resected normal parenchymal volume (RNLV), then assessing the performance and value of the model in clinical practice.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
selective hepatectomies;
histologically confirmed as HCC and ICC
complete and accessible data
Disqualifiers
any history of Associated Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS)
any history of portal vein embolism (PVE)
any history of tumor rupture
emergency surgery
Trial population
1133 consecutive patients diagnosed with hepatocellular carcinoma (HCC) and intracholangiocarcinoma underwent hepatectomies.
Trial design
Case-control
Retrospective
Treatments tested in this trial
the different definitions of PHLF according to 50-50 criteria and ISGLS criteria
Diagnostic testOur study respectively defined the PHLF according to the 50-50 criteria and the ISGLS criteria in literature review.
Treatment groups
Trial outcomes
Primary outcomes
Probability of PHLF was predicted with our individual model based on RNLV.
In our center, an increase international normalized ratio greater than 1.15 and concomitant hyperbilirubinemia more than 23μmol/L on or after postoperative day 5 would be defined as PHLF, according to the International Study Group of Liver Surgery.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.